Abdominal Aortic Aneurysm
Endovascular vs Open Aortic Repair in the UK
ISRCTN84567219
RecruitingEnrolled
15
Sites
280
Target
112
Enrolled
Recruiting
Phase
Lead: Professor Robert Sheridan
EVAAR-UK
A landmark UK trial comparing keyhole and open surgery for aortic aneurysm
About This Trial
This trial is comparing two types of surgery for a swelling in the main blood vessel in your abdomen (called an aortic aneurysm). We want to find out which approach leads to better long-term outcomes for patients. Both keyhole (endovascular) and open surgical repair are well-established NHS treatments, but we genuinely do not know which gives better results with modern devices and techniques.
How to Join
Taking part is straightforward. Here is what happens.
Speak to your surgeon — Ask your vascular team if this trial is right for you
Check eligibility — The team will confirm you meet the entry criteria
Give consent — Read the information sheet and ask any questions
Join the trial — You will be randomly assigned to keyhole or open surgery
Am I Eligible?
You may be able to take part if you meet the following criteria.
You are aged 55 to 85
You have been diagnosed with an abdominal aortic aneurysm measuring 5.5 cm or more
Your surgeon considers you fit enough for either type of operation
You are able to attend follow-up appointments for up to 5 years
Inclusion Criteria
Adults aged 55-85 with infrarenal AAA ≥5.5 cm on CT angiography; anatomically suitable for both EVAR and open repair; ASA grade I-III; able to provide informed consent
Exclusion Criteria
Ruptured or symptomatic aneurysm requiring emergency repair; previous aortic surgery; suprarenal or thoracoabdominal aneurysm; severe cardiac, respiratory or renal disease precluding general anaesthesia; life expectancy <2 years from comorbidity
Latest Updates
EVAAR-UK trial passes 100-participant milestone across 15 NHS sites
Recruitment to the national trial comparing endovascular and open repair of abdominal aortic aneurysms has now exceeded 100 patients, keeping the study on track for its 280-participant target.